WO2011003423A1 - Manufacture of 4-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and 1-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-3,3-dimethyl-piperazine - Google Patents

Manufacture of 4-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and 1-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-3,3-dimethyl-piperazine Download PDF

Info

Publication number
WO2011003423A1
WO2011003423A1 PCT/DK2010/050177 DK2010050177W WO2011003423A1 WO 2011003423 A1 WO2011003423 A1 WO 2011003423A1 DK 2010050177 W DK2010050177 W DK 2010050177W WO 2011003423 A1 WO2011003423 A1 WO 2011003423A1
Authority
WO
WIPO (PCT)
Prior art keywords
piperazine
chloro
indan
phenyl
trimethyl
Prior art date
Application number
PCT/DK2010/050177
Other languages
French (fr)
Inventor
Svend Treppendahl
Allan Carsten Dahl
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Priority to AU2010268892A priority Critical patent/AU2010268892B2/en
Priority to CN2010800309960A priority patent/CN102471289A/en
Priority to US13/382,378 priority patent/US8501947B2/en
Priority to JP2012518754A priority patent/JP2012532153A/en
Priority to CA2766607A priority patent/CA2766607A1/en
Priority to EP10730348A priority patent/EP2451789A1/en
Publication of WO2011003423A1 publication Critical patent/WO2011003423A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to resolvation methods for manufacture of 4- (( 1 R,3 S)-6-Chloro-3-phenyl-indan- 1 -yl)- 1 ,2,2-trimethyl-piperazine and 1 -(( 1 R,3 S)-6- Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine and pharmaceutically acceptable salts thereof.
  • the compounds of the present invention 4-((lR,3S)-6-Chloro-3 -phenyl- indan- l-yl)-l,2,2-trimethyl-piperazine (I) and l-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)- 3,3-dimethyl-piperazine (II) hereinafter referred to as Compound (I) and (II) have the respective molecular structures depicted below.
  • a group of trans isomers of 3-aryl-l-(l-piperazinyl)indanes substituted in the 2- and/or 3 -position of the piperazine ring has been described in WO 93/22293 and in Klaus P. Bogeso, Drug Hunting, the Medicinal Chemistry of l-Piperazino-3- phenylindans and Related Compounds, 1998, ISBN 87-88085-10-4 (cf. e.g. compound 69 in table 3, p. 47 and in table 9A, p. 101).
  • the compounds are described as having high affinity for dopamine Di and D 2 receptors and the 5-HT 2 receptor and are suggested to be useful for treatment of several diseases in the central nervous system, including schizophrenia.
  • Trans racemic 4-((6-Chloro-3-phenyl-indan- 1 -yl)- 1 ,2,2-trimethyl-piperazine and trans racemic l-(6-Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine may e.g. be synthesized analogously to the methods outlined in B ⁇ ges ⁇ et al, J. Med. Chem.,
  • Compound (I) is a potent DiZD 2 antagonists showing some Di selectivity in vitro while in vivo it is equipotent as Di and D 2 antagonist.
  • the compound is also described as a potent 5-HT 2 antagonist and as having high affinity for ⁇ i adrenoceptors.
  • Compound (II) displays a similar receptor profile and pharmacological activity as Compound (I). Summary of the invention
  • the present inventors have found that a high yield and a high enantiomeric excess of 4-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-l,2,2-trimethyl-piperazine and 1- ((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine can be obtained by resolvation of their respective racemates with a chiral salt-forming acid.
  • the present invention provides a process for the manufacture of 4-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-l,2,2-trimethyl- piperazine or a pharmaceutically acceptable salt thereof comprising the step of mixing trans 4-(6-chloro-3-phenyl-indan-l-yl)-l,2,2-trimethyl-piperazine and L-(+)-tartaric acid in a polar solvent to obtain 4-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-l,2,2- trimethyl-piperazine or a pharmaceutically acceptable salt thereof.
  • the present invention provides a process for the manufacture of 4-(( 1 R,3 S)-6-Chloro-3 -phenyl- indan- 1 -yl)- 1 ,2,2-trimethyl-piperazine or a pharmaceutically acceptable salt thereof comprising the step of precipitating a product from a solution comprising trans 4-(6-chloro-3 -phenyl- indan- 1 -yl)- 1 ,2,2- trimethyl-piperazine and L-(+)-tartaric acid, in a polar solvent to obtain 4-((lR,3S)-6- Chloro-3-phenyl- indan- l-yl)-l,2,2-trimethyl-piperazine or a pharmaceutically acceptable salt thereof.
  • the present invention provides a process for the manufacture of 4-(( 1 R,3 S)-6-Chloro-3 -phenyl- indan- 1 -yl)- 1 ,2,2-trimethyl-piperazine or a pharmaceutically acceptable salt thereof comprising the steps of
  • the present invention relates to a compound which is 4-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-l,2,2-trimethyl-piperazine L-(+)-tartrate.
  • the present invention relates to a process for the manufacture of l-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine or a pharmaceutically acceptable salt thereof comprising the step of mixing trans l-(6- chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine with D-(-)-tartaric acid in a polar solvent to obtain l-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl- piperazine or a pharmaceutically acceptable salt thereof.
  • the present invention relates to a process for the manufacture of l-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine or a pharmaceutically acceptable salt thereof comprising the step of precipitating a product from a solution comprising trans l-(6-chloro-3-phenyl-indan-l-yl)-3,3- dimethyl-piperazine and D-(-)-tartaric acid in a polar solvent to obtain l-((lR,3S)-6- Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine or a pharmaceutically acceptable salt thereof.
  • the present invention relates to a process for the manufacture of l-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine or a pharmaceutically acceptable salt thereof comprising the steps of
  • Compound (I) and Compound (II) respectively is intended to designate any form of the compound, such as the free base,
  • pharmaceutically acceptable salts thereof e.g. pharmaceutically acceptable acid addition salts, such as succinate and malonate salts, hydrates or solvates of the free base or salts thereof, as well as anhydrous forms, amorphous forms, or crystalline forms.
  • pharmaceutically acceptable acid addition salts such as succinate and malonate salts, hydrates or solvates of the free base or salts thereof, as well as anhydrous forms, amorphous forms, or crystalline forms.
  • chiral salt-forming acid is defined as an organic acid with at least one chiral carbon atom
  • a chiral salt-forming acid of the present invention is meant to indicate L-(+)-tartaric acid and D-(-)-tartaric acid.
  • polar solvent is defined as a liquid composed of polar molecules. Examples include water, alcohols such as ethanol and propanol, organic acids such as formic acid, ketones such as acetone, tetrahydrofurane and mixtures hereof.
  • a pharmaceutically acceptable salt of a compound of Formula I or II includes pharmaceutically acceptable acid addition salts.
  • Acid addition salts include salts of inorganic acids as well as organic acids. Representative examples of suitable inorganic acids include hydrochloric, hydrobromic, hydro iodic,
  • suitable organic acids include formic, acetic, trichloroacetic, trifluoroacetic, propionic, benzoic, cinnamic, citric, fumaric, glycolic, itaconic, lactic, methanesulfonic, maleic, malic, malonic, mandelic, oxalic, picric, pyruvic, salicylic, succinic, methane sulfonic, ethanesulfonic, tartaric, ascorbic, pamoic, bismethylene salicylic, ethanedisulfonic, gluconic, citraconic, aspartic, stearic, palmitic, EDTA, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, p-toluenesulfonic acids, theophylline acetic acids, as well as the
  • heating to an "appropriate temperature” indicates that the composition is heated to a temperature suitable for obtaining a solution, such as above room temperature such as >40°C, such as >45°C, such as >50°C, such as >55°C, such as >60°C, such as >65°C, such as >70°C limited by the reflux
  • Recrystallization is a procedure for purifying compounds. Recrystallization can be performed by e.g. single-solvent
  • yield of a synthesis process represents the total yield of synthesis product, including the salts of both enantiomers relative to the theoretical amount of racemate salt.
  • enantiomeric excess is abbreviated ee and defined as the absolute difference between the mole fractions of each enantiomer of a compound.
  • trans 4-(6-chloro-3-phenylindan-l-yl)- 1,2,2- trimethyl-piperazine i.e. without any specific indication of the enantiomer form (e.g. using (+) and (-), or using the R/S-convention, refers to a mixture of the two enantiomers, 4-((1R, J5)-6-chloro-3-phenylindan-l-yl)-l,2,2-trimethyl piperazine (I) and 4-((1S, Ji?)-6-chloro-3-phenylindan-l-yl)-l,2,2-trimethyl piperazine.
  • the content of the enantiomer corresponding to that of
  • Compound (I) is at least 30 % of the mixture, such as at least 40 % such as at least 50 %, i.e. at least as the racemate.
  • the same principle applies for "trans- l-(6-Chloro-3 - phenyl-indan-l-yl)-3,3-dimethyl-piperazine".
  • 1,2,2-trimethyl-piperazine refers to the racemate.
  • the same principle applies for "trans racemic 1 -(6-Chloro-3-phenyl-indan- 1 -yl)-3 ,3-dimethyl-piperazine".
  • a “racemate” is an optically inactive compound that has substantially equal amounts of S and R enantiomers of a chiral molecule.
  • the present invention relates to a process for manufacture of 4-((lR,3S)-6- Chloro-3-phenyl-indan-l-yl)-l,2,2-trimethyl-piperazine (Compound (I)) comprising resolvation of trans 4-((6-Chloro-3-phenyl-indan- 1 -yl)- 1 ,2,2-trimethyl-piperazine with L-(+)-tartaric acid.
  • the present invention also relates to a process for manufacture of 1-((1R,3S)- 6-Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine (Compound (H)) comprising resolvation of trans l-((6-Chloro-3-phenyl-indan-l-yl)- 3,3-dimethyl-piperazine with D-(-)-tartaric acid.
  • the present invention relates to processes wherein the racemate is mixed with a chiral salt-forming acid of the present invention in a polar solvent.
  • the mixture may optionally be heated to an appropriate temperature to obtain a solution of the racemate and the chiral salt-forming acid.
  • Subsequent precipitation of the enantiomers may be obtained e.g. by cooling or evaporation and the precipitate may be isolated and optionally dried. It is the experience of the inventors that
  • recrystallisation of the precipitate may increase the enantiomeric excess.
  • the choice of solvent and conditions for the resolvation process e.g. temperature and
  • stoichiometry of the starting materials may be used to optimize the yield and enantiomeric excess of the desired enantiomer.
  • the resolvation methods of the present invention have been found to provide a yield of at least >40 % under certain circumstances up to about 90 % which is strikingly higher than the yield obtained by the resolvation method described in B ⁇ ges ⁇ et al, J. Med. Chem., 1995, 38, p. 4380-4392 wherein (+)-ditoluoyl tartaric acid is used for resolvation of trans racemic 4-((6-Chloro-3-phenyl- indan- 1-yl)- 1,2,2- trimethyl-piperazine. Furthermore, the processes of the present invention are much more suitable for upscaling.
  • trans racemic l-(6-Chloro- 3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine) was attempted resolved with (+)- ditoluoyl tartataric acid, (+)-dibenzoyl tartaric acid, (+)-camphorsulfonic acid, (-)- mandelic acid and L-glutamic acid with the same disadvantages.
  • the present invention relates to a process for the manufacture of 4-(( 1 R,3 S)-6-Chloro-3 -phenyl- indan- 1 -yl)- 1 ,2,2-trimethyl-piperazine or a pharmaceutically acceptable salt thereof comprising the step of mixing trans 4-(6- chloro-3-phenyl- indan- l-yl)-l,2,2-trimethyl-piperazine with L-(+)-tartaric acid in a polar solvent to obtain 4-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-l,2,2-trimethyl- piperazine or a pharmaceutically acceptable salt thereof.
  • the mixture of trans 4-(6-chloro-3-phenyl- indan- 1- yl)-l,2,2-trimethyl-piperazine and L-(+)-tartaric acid in a polar solvent is brought into conditions suitable for obtaining a solution of the trans 4-(6-chloro-3-phenyl- indan- 1- yl)-l,2,2-trimethyl-piperazine and L-(+)-tartaric acid.
  • said mixture of trans 4-(6-chloro-3 -phenyl- indan- l-yl)-l,2,2-trimethyl-piperazine and L-(+)-tartaric acid in a polar solvent is heated to an appropriate temperature to obtain a solution of the trans 4-(6-chloro-3 -phenyl- indan- l-yl)-l,2,2-trimethyl-piperazine and L-(+)-tartaric acid.
  • the present invention relates to a process for the manufacture of 4-(( 1 R,3 S)-6-Chloro-3 -phenyl- indan- 1 -yl)- 1 ,2,2-trimethyl-piperazine or a pharmaceutically acceptable salt thereof comprising the step of precipitating a product from a solution comprising trans 4-(6-chloro-3 -phenyl- indan-1-yl)- 1,2,2- trimethyl-piperazine and L-(+)-tartaric acid in a polar solvent to obtain 4-((lR,3S)-6- Chloro-3-phenyl-indan-l-yl)-l,2,2-trimethyl-piperazine or a pharmaceutically acceptable salt thereof.
  • the present invention relates to a process for the manufacture of 4-(( 1 R,3 S)-6-Chloro-3 -phenyl- indan- 1 -yl)- 1 ,2,2-trimethyl-piperazine or a pharmaceutically acceptable salt thereof comprising the steps of
  • the process comprises a subsequent step in which the precipitate is recrystallised after step d) or e).
  • the trans 4-(6-chloro-3-phenyl- indan-1-yl)- 1,2,2- trimethyl-piperazine used in the process for manufacture of 4-((lR,3S)-6-Chloro-3- phenyl- indan- l-yl)-l,2,2-trimethyl-piperazine is the trans racemic 4-(6-chloro-3-phe nyl- indan- 1 -yl)- 1 ,2,2-trimethyl-piperazine.
  • 4-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-l,2,2- trimethyl-piperazine L-(+)-tartrate is an intermediate or end product of the process.
  • said 4-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-l,2,2- trimethyl-piperazine L-(+)-tartrate is in a crystalline form.
  • the present invention relates to a compound which is 4- ((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-l,2,2-trimethyl-piperazine L-(+)-tartrate.
  • said 4-((lR,3S)-6-Chloro-3-phenyl- indan-1-yl)- 1,2,2- trimethyl-piperazine L-(+)-tartrate is in a crystalline form.
  • the present invention also relates to a process for manufacture of 1-((1R,3S)- 6-Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine (Compound (H)) by resolvation of trans l-(6-Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine with D-(-)-tartaric acid.
  • the present invention relates to a process for the manufacture of l-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine or a pharmaceutically acceptable salt thereof comprising the step of mixing trans l-(6- chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine with D-(-)-tartaric acid in a polar solvent to obtain 4-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl- piperazine or a pharmaceutically acceptable salt thereof.
  • the mixture of trans l-((6-chloro-3-phenyl-indan-l- yl)-3,3-dimethyl-piperazine and D-(-)-tartaric acid in a polar solvent is brought into conditions suitable for obtaining a solution of the trans l-((6-chloro-3-phenyl-indan-l- yl)-3,3-dimethyl-piperazine and D-(-)-tartaric acid.
  • said mixture of trans l-((6-chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine and D-(-)-tartaric acid in a polar solvent is heated to an appropriate temperature to obtain a solution of the trans l-((6-chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine and D-(-)-tartaric acid.
  • the present invention relates to a process for the manufacture of l-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine or a pharmaceutically acceptable salt thereof comprising the step of precipitating a product from a solution comprising trans l-(6-chloro-3-phenyl-indan-l-yl)-3,3-d imethyl-piperazine and D-(-)-tartaric acidin a polar solvent to obtain l-((lR,3S)-6- Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine or a pharmaceutically acceptable salt thereof.
  • the present invention relates to, a process for the manufacture of l-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine or a pharmaceutically acceptable salt thereof comprising the steps of
  • said process comprises a subsequent step in which the precipitate is recrystallised after step d) or e).
  • the trans l-((6-chloro-3-phenyl-indan-l-yl)-3,3- dimethyl-piperazine used in the process for manufacture of l-((lR,3S)-6-Chloro-3- phenyl-indan-l-yl)-3,3-dimethyl-piperazine is the trans racemic l-((6-chloro-3-phe nyl-indan-l-yl)-3,3-dimethyl-piperazine.
  • l-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl- piperazine hemi D-(-)-tartrate is an intermediate or end product of the process.
  • said l-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl- piperazine hemi D-(-)-tartrate is in a crystalline form.
  • the polar solvent applied in the processes of the present invention are chosen from water, a ketone, an alcohol, an organic acid or mixtures hereof such as water, acetone, ethanol, n-propanol, formic acid or mixtures hereof.
  • the purified chiral acid addition salt of Compound (I) or (II) may be used as starting material in further processes in which the chiral acid addition salt of the present invention is dissolved, the free base form is optionally obtained, and the desired salt, preferably a pharmaceutically acceptable salt is achieved by precipitation with an appropriate acid.
  • the pharmaceutically acceptable salt is a succinate salt or a malonate salt.
  • the pharmaceutically acceptable salt is in the form of a crystalline hydrogen succinate salt of Compound (I) e.g., crystal form alpha or beta of the hydrogen succinate salt of Compound (I), or a crystalline hydrogen malonate salt of Compound (I).
  • the succinate salt and malonate salt of Compound (I) are described in WO 2005/016900.
  • the pharmaceutically acceptable salt is a tartrate salt or a malate salt.
  • the pharmaceutically acceptable salt is in the form of a crystalline hydrogen tartrate salt of Compound (II) or a hydrogen malate salt of Compound (II). The tartrate salt and malate salt of Compound
  • (+)-tartrate acetone
  • Example 4 4-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-l,2,2-trimethyl-piperazine L- (+)-tartrate, ethanol and formic acid.
  • the product (2.00 g) was recrystallised from a mixture of ethanol (100 mL) and water (10 mL) at reflux. The solution was stirred while cooled down to room temperature and stirred for a week at room temperature. The precipitate was filtered off and dried in the hood at room temperature. Yield 0.81 g (40.5 %).
  • Example 8 l-((lS,3R)-6-Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine hemi L-(+)-tartrate, acetone.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

The present invention relates to a process for the manufacture of 4-((1R,3S)-6-Chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine or a pharmaceutically acceptable salt thereof and a process for the manufacture of 1-((1R,3S)-6-Chloro-3-phenyl-indan-1-yl)-3,3-dimethyl-piperazine or a pharmaceutically acceptable salt thereof.

Description

Manufacture of 4-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-l,2,2-trimethyl- piperazine and l-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl- piperazine Field of the invention
The present invention relates to resolvation methods for manufacture of 4- (( 1 R,3 S)-6-Chloro-3-phenyl-indan- 1 -yl)- 1 ,2,2-trimethyl-piperazine and 1 -(( 1 R,3 S)-6- Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine and pharmaceutically acceptable salts thereof.
Background
The compounds of the present invention 4-((lR,3S)-6-Chloro-3 -phenyl- indan- l-yl)-l,2,2-trimethyl-piperazine (I) and l-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)- 3,3-dimethyl-piperazine (II) hereinafter referred to as Compound (I) and (II) have the respective molecular structures depicted below.
Figure imgf000002_0001
(I) (H)
A group of trans isomers of 3-aryl-l-(l-piperazinyl)indanes substituted in the 2- and/or 3 -position of the piperazine ring has been described in WO 93/22293 and in Klaus P. Bogeso, Drug Hunting, the Medicinal Chemistry of l-Piperazino-3- phenylindans and Related Compounds, 1998, ISBN 87-88085-10-4 (cf. e.g. compound 69 in table 3, p. 47 and in table 9A, p. 101). The compounds are described as having high affinity for dopamine Di and D2 receptors and the 5-HT2 receptor and are suggested to be useful for treatment of several diseases in the central nervous system, including schizophrenia.
Trans racemic 4-((6-Chloro-3-phenyl-indan- 1 -yl)- 1 ,2,2-trimethyl-piperazine and trans racemic l-(6-Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine may e.g. be synthesized analogously to the methods outlined in Bøgesø et al, J. Med. Chem.,
1995, 38, p. 4380-4392 and in WO 93/22293. Manufacture of Compound (I) by resolvation of trans racemic 4-((6-Chloro-3-phenyl-indan-l-yl)-l,2,2-trimethyl- piperazine has been described by Bøgesø et al. in J. Med. Chem., 1995, 38, p. 4380- 4392, see table 5, compound (-)-38. The process described comprises the use of (+)- ditoluoyl tartaric acid for resolvation in ethylacetate, and Compound (I) is isolated as the fumarate salt.
The synthesis of Compound (II) from optically pure starting materials has been described in WO 2005/016900, WO 2005/016901 and WO 2006/086984.
Synthesis of Compound (I) from Compound (II) by N-alkylation is disclosed in WO
2005/016900 (p.31, example 12). A crystalline hydrogen tartrate salt of Compound
(II) has been disclosed in WO 2006/086985.
Bøgesø et al., J. Med. Chem., 1995, 38, p. 4380-4392 discloses that
Compound (I) is a potent DiZD2 antagonists showing some Di selectivity in vitro while in vivo it is equipotent as Di and D2 antagonist. The compound is also described as a potent 5-HT2 antagonist and as having high affinity for αi adrenoceptors. As disclosed in WO 2005/016901 Compound (II) displays a similar receptor profile and pharmacological activity as Compound (I). Summary of the invention
The present inventors have found that a high yield and a high enantiomeric excess of 4-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-l,2,2-trimethyl-piperazine and 1- ((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine can be obtained by resolvation of their respective racemates with a chiral salt-forming acid.
Accordingly, in one embodiment, the present invention provides a process for the manufacture of 4-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-l,2,2-trimethyl- piperazine or a pharmaceutically acceptable salt thereof comprising the step of mixing trans 4-(6-chloro-3-phenyl-indan-l-yl)-l,2,2-trimethyl-piperazine and L-(+)-tartaric acid in a polar solvent to obtain 4-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-l,2,2- trimethyl-piperazine or a pharmaceutically acceptable salt thereof.
In another embodiment, the present invention provides a process for the manufacture of 4-(( 1 R,3 S)-6-Chloro-3 -phenyl- indan- 1 -yl)- 1 ,2,2-trimethyl-piperazine or a pharmaceutically acceptable salt thereof comprising the step of precipitating a product from a solution comprising trans 4-(6-chloro-3 -phenyl- indan- 1 -yl)- 1 ,2,2- trimethyl-piperazine and L-(+)-tartaric acid, in a polar solvent to obtain 4-((lR,3S)-6- Chloro-3-phenyl- indan- l-yl)-l,2,2-trimethyl-piperazine or a pharmaceutically acceptable salt thereof.
In another embodiment, the present invention provides a process for the manufacture of 4-(( 1 R,3 S)-6-Chloro-3 -phenyl- indan- 1 -yl)- 1 ,2,2-trimethyl-piperazine or a pharmaceutically acceptable salt thereof comprising the steps of
a) mixing trans 4-(6-chloro-3-phenyl- indan- 1 -yl)- 1 ,2,2-trimethyl-piperazine and L-(+)-tartaric acid in a polar solvent;
b) optionally heating the obtained mixture to an appropriate temperature to obtain a solution of the trans 4-(6-chloro-3-phenyl- indan- l-yl)-l,2,2-trimethyl-piperazine and L-(+)-tartaric acid;
c) cooling the solution obtained in b) until precipitation;
d) isolating the precipitate obtained in c);
e) optionally drying the precipitate obtained in d);
to obtain 4-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-l,2,2-trimethyl-piperazine or a pharmaceutically acceptable salt thereof.
In another embodiment, the present invention relates to a compound which is 4-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-l,2,2-trimethyl-piperazine L-(+)-tartrate.
In one embodiment, the present invention relates to a process for the manufacture of l-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine or a pharmaceutically acceptable salt thereof comprising the step of mixing trans l-(6- chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine with D-(-)-tartaric acid in a polar solvent to obtain l-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl- piperazine or a pharmaceutically acceptable salt thereof.
In another embodiment, the present invention relates to a process for the manufacture of l-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine or a pharmaceutically acceptable salt thereof comprising the step of precipitating a product from a solution comprising trans l-(6-chloro-3-phenyl-indan-l-yl)-3,3- dimethyl-piperazine and D-(-)-tartaric acid in a polar solvent to obtain l-((lR,3S)-6- Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine or a pharmaceutically acceptable salt thereof.
In another embodiment, the present invention relates to a process for the manufacture of l-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine or a pharmaceutically acceptable salt thereof comprising the steps of
a) mixing trans l-(6-chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine and D- (-)-tartaric acid in a polar solvent;
b) optionally heating the obtained mixture to an appropriate temperature to obtain a solution of the trans l-((6-chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine and D-(-)-tartaric acid;
c) cooling the solution obtained in b) until precipitation;
d) isolating the precipitate obtained in c);
e) optionally drying the precipitate obtained in d);
to obtain l-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine or a pharmaceutically acceptable salt thereof.
Definitions
As described herein, Compound (I) and Compound (II) respectively, is intended to designate any form of the compound, such as the free base,
pharmaceutically acceptable salts thereof, e.g. pharmaceutically acceptable acid addition salts, such as succinate and malonate salts, hydrates or solvates of the free base or salts thereof, as well as anhydrous forms, amorphous forms, or crystalline forms.
As described herein, the term "chiral salt-forming acid" is defined as an organic acid with at least one chiral carbon atom, "a chiral salt-forming acid of the present invention" is meant to indicate L-(+)-tartaric acid and D-(-)-tartaric acid.
As described herein the term "polar solvent" is defined as a liquid composed of polar molecules. Examples include water, alcohols such as ethanol and propanol, organic acids such as formic acid, ketones such as acetone, tetrahydrofurane and mixtures hereof.
As described herein "a pharmaceutically acceptable salt" of a compound of Formula I or II includes pharmaceutically acceptable acid addition salts. Acid addition salts include salts of inorganic acids as well as organic acids. Representative examples of suitable inorganic acids include hydrochloric, hydrobromic, hydro iodic,
phosphoric, sulfuric, sulfamic, nitric acids and the like. Representative examples of suitable organic acids include formic, acetic, trichloroacetic, trifluoroacetic, propionic, benzoic, cinnamic, citric, fumaric, glycolic, itaconic, lactic, methanesulfonic, maleic, malic, malonic, mandelic, oxalic, picric, pyruvic, salicylic, succinic, methane sulfonic, ethanesulfonic, tartaric, ascorbic, pamoic, bismethylene salicylic, ethanedisulfonic, gluconic, citraconic, aspartic, stearic, palmitic, EDTA, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, p-toluenesulfonic acids, theophylline acetic acids, as well as the 8-halotheophyllines, for example 8-bromotheophylline and the like.
In the context of the present invention the terms "resolvation" and "resolution" are use interchangeably and describes a process by which a racemate is separated into its two enantiomers.
In the present context, heating to an "appropriate temperature" indicates that the composition is heated to a temperature suitable for obtaining a solution, such as above room temperature such as >40°C, such as >45°C, such as >50°C, such as >55°C, such as >60°C, such as >65°C, such as >70°C limited by the reflux
temperature of the solvent. Dependent on the solvent used "appropriate temperature" might indicate reflux temperature, i.e. the composition is heated to reflux.
In the present context, "reflux" is a technique involving the condensation of vapors and the return of this condensate to the system from which it originated.
In the present context, "recrystallization" is a procedure for purifying compounds. Recrystallization can be performed by e.g. single-solvent
recrystallization, mult i- solvent recrystallization or hot fϊltration-recrystallization.
In the present context, "yield" of a synthesis process represents the total yield of synthesis product, including the salts of both enantiomers relative to the theoretical amount of racemate salt.
In the present context, "enantiomeric excess" is abbreviated ee and defined as the absolute difference between the mole fractions of each enantiomer of a compound.
As used herein, the term "trans 4-(6-chloro-3-phenylindan-l-yl)- 1,2,2- trimethyl-piperazine", i.e. without any specific indication of the enantiomer form (e.g. using (+) and (-), or using the R/S-convention, refers to a mixture of the two enantiomers, 4-((1R, J5)-6-chloro-3-phenylindan-l-yl)-l,2,2-trimethyl piperazine (I) and 4-((1S, Ji?)-6-chloro-3-phenylindan-l-yl)-l,2,2-trimethyl piperazine. However, in this context preferably the content of the enantiomer corresponding to that of
Compound (I) is at least 30 % of the mixture, such as at least 40 % such as at least 50 %, i.e. at least as the racemate. The same principle applies for "trans- l-(6-Chloro-3 - phenyl-indan-l-yl)-3,3-dimethyl-piperazine".
As used herein, the term "trans racemic 4-((6-Chloro-3 -phenyl- indan-1-yl)-
1,2,2-trimethyl-piperazine" refers to the racemate. The same principle applies for "trans racemic 1 -(6-Chloro-3-phenyl-indan- 1 -yl)-3 ,3-dimethyl-piperazine".
In the present context, a "racemate" is an optically inactive compound that has substantially equal amounts of S and R enantiomers of a chiral molecule.
Detailed description of the invention
The present invention relates to a process for manufacture of 4-((lR,3S)-6- Chloro-3-phenyl-indan-l-yl)-l,2,2-trimethyl-piperazine (Compound (I)) comprising resolvation of trans 4-((6-Chloro-3-phenyl-indan- 1 -yl)- 1 ,2,2-trimethyl-piperazine with L-(+)-tartaric acid.
The present invention also relates to a process for manufacture of 1-((1R,3S)- 6-Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine (Compound (H)) comprising resolvation of trans l-((6-Chloro-3-phenyl-indan-l-yl)- 3,3-dimethyl-piperazine with D-(-)-tartaric acid.
In brief, the present invention relates to processes wherein the racemate is mixed with a chiral salt-forming acid of the present invention in a polar solvent. The mixture may optionally be heated to an appropriate temperature to obtain a solution of the racemate and the chiral salt-forming acid. Subsequent precipitation of the enantiomers may be obtained e.g. by cooling or evaporation and the precipitate may be isolated and optionally dried. It is the experience of the inventors that
recrystallisation of the precipitate may increase the enantiomeric excess. The choice of solvent and conditions for the resolvation process e.g. temperature and
stoichiometry of the starting materials may be used to optimize the yield and enantiomeric excess of the desired enantiomer.
The resolvation methods of the present invention have been found to provide a yield of at least >40 % under certain circumstances up to about 90 % which is strikingly higher than the yield obtained by the resolvation method described in Bøgesø et al, J. Med. Chem., 1995, 38, p. 4380-4392 wherein (+)-ditoluoyl tartaric acid is used for resolvation of trans racemic 4-((6-Chloro-3-phenyl- indan- 1-yl)- 1,2,2- trimethyl-piperazine. Furthermore, the processes of the present invention are much more suitable for upscaling. The resolution with unsubstituted tartaric acid gives easy filterable crystals with a high speed of filtration and the possibility of washing the filter cake. The diastereomeric crystallisations are very efficient giving often enantiomeric purities up to ee values of 98 % of the first crystallisation. In contrast, resolvation with (+)-ditoluoyl tartaric acid by the present inventors resulted in a less filterable precipitate requiring more steps of recrystallization and thus, this method is not suitable for use in a production scale.
Trans racemic 4-((6-Chloro-3-phenyl-indan- 1 -yl)- 1 ,2,2-trimethyl-piperazine was also attempted resolved with (+)-dibenzoyl tartaric acid, (+)-camphorsulfonic acid, (-)-mandelic acid and L-glutamic acid. However, these alternatives suffers from either poor ability to crystallize or, in cases where crystals were obtained, lack of enantiomeric excess of the desired enantiomer. Likewise, trans racemic l-(6-Chloro- 3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine) was attempted resolved with (+)- ditoluoyl tartataric acid, (+)-dibenzoyl tartaric acid, (+)-camphorsulfonic acid, (-)- mandelic acid and L-glutamic acid with the same disadvantages.
In a first embodiment, the present invention relates to a process for the manufacture of 4-(( 1 R,3 S)-6-Chloro-3 -phenyl- indan- 1 -yl)- 1 ,2,2-trimethyl-piperazine or a pharmaceutically acceptable salt thereof comprising the step of mixing trans 4-(6- chloro-3-phenyl- indan- l-yl)-l,2,2-trimethyl-piperazine with L-(+)-tartaric acid in a polar solvent to obtain 4-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-l,2,2-trimethyl- piperazine or a pharmaceutically acceptable salt thereof.
In a further embodiment, the mixture of trans 4-(6-chloro-3-phenyl- indan- 1- yl)-l,2,2-trimethyl-piperazine and L-(+)-tartaric acid in a polar solvent is brought into conditions suitable for obtaining a solution of the trans 4-(6-chloro-3-phenyl- indan- 1- yl)-l,2,2-trimethyl-piperazine and L-(+)-tartaric acid. Preferably, said mixture of trans 4-(6-chloro-3 -phenyl- indan- l-yl)-l,2,2-trimethyl-piperazine and L-(+)-tartaric acid in a polar solvent is heated to an appropriate temperature to obtain a solution of the trans 4-(6-chloro-3 -phenyl- indan- l-yl)-l,2,2-trimethyl-piperazine and L-(+)-tartaric acid.
In another embodiment, the present invention relates to a process for the manufacture of 4-(( 1 R,3 S)-6-Chloro-3 -phenyl- indan- 1 -yl)- 1 ,2,2-trimethyl-piperazine or a pharmaceutically acceptable salt thereof comprising the step of precipitating a product from a solution comprising trans 4-(6-chloro-3 -phenyl- indan-1-yl)- 1,2,2- trimethyl-piperazine and L-(+)-tartaric acid in a polar solvent to obtain 4-((lR,3S)-6- Chloro-3-phenyl-indan-l-yl)-l,2,2-trimethyl-piperazine or a pharmaceutically acceptable salt thereof.
In another embodiment, the present invention relates to a process for the manufacture of 4-(( 1 R,3 S)-6-Chloro-3 -phenyl- indan- 1 -yl)- 1 ,2,2-trimethyl-piperazine or a pharmaceutically acceptable salt thereof comprising the steps of
a) mixing trans 4-(6-chloro-3-phenyl- indan- 1 -yl)- 1 ,2,2-trimethyl-piperazine and L-(+)-tartaric acid in a polar solvent;
b) optionally heating the obtained mixture to an appropriate temperature to obtain a solution of the trans 4-(6-chloro-3-phenyl- indan- l-yl)-l,2,2-trimethyl-piperazine and L-(+)-tartaric acid;
c) cooling the solution obtained in b) until precipitation;
d) isolating the precipitate obtained in c);
e) optionally drying the precipitate obtained in d);
to obtain 4-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-l,2,2-trimethyl-piperazine or a pharmaceutically acceptable salt thereof. Optionally, the process comprises a subsequent step in which the precipitate is recrystallised after step d) or e).
In a preferred embodiment, the trans 4-(6-chloro-3-phenyl- indan-1-yl)- 1,2,2- trimethyl-piperazine used in the process for manufacture of 4-((lR,3S)-6-Chloro-3- phenyl- indan- l-yl)-l,2,2-trimethyl-piperazine is the trans racemic 4-(6-chloro-3-phe nyl- indan- 1 -yl)- 1 ,2,2-trimethyl-piperazine.
In one embodiment, 4-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-l,2,2- trimethyl-piperazine L-(+)-tartrate is an intermediate or end product of the process. In a preferred embodiment, said 4-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-l,2,2- trimethyl-piperazine L-(+)-tartrate is in a crystalline form.
In one embodiment, the present invention relates to a compound which is 4- ((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-l,2,2-trimethyl-piperazine L-(+)-tartrate. In a preferred embodiment, said 4-((lR,3S)-6-Chloro-3-phenyl- indan-1-yl)- 1,2,2- trimethyl-piperazine L-(+)-tartrate is in a crystalline form.
The present invention also relates to a process for manufacture of 1-((1R,3S)- 6-Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine (Compound (H)) by resolvation of trans l-(6-Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine with D-(-)-tartaric acid.
Thus, in one embodiment, the present invention relates to a process for the manufacture of l-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine or a pharmaceutically acceptable salt thereof comprising the step of mixing trans l-(6- chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine with D-(-)-tartaric acid in a polar solvent to obtain 4-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl- piperazine or a pharmaceutically acceptable salt thereof.
In a further embodiment, the mixture of trans l-((6-chloro-3-phenyl-indan-l- yl)-3,3-dimethyl-piperazine and D-(-)-tartaric acid in a polar solvent is brought into conditions suitable for obtaining a solution of the trans l-((6-chloro-3-phenyl-indan-l- yl)-3,3-dimethyl-piperazine and D-(-)-tartaric acid. Preferably, said mixture of trans l-((6-chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine and D-(-)-tartaric acid in a polar solvent is heated to an appropriate temperature to obtain a solution of the trans l-((6-chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine and D-(-)-tartaric acid..
In another embodiment, the present invention relates to a process for the manufacture of l-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine or a pharmaceutically acceptable salt thereof comprising the step of precipitating a product from a solution comprising trans l-(6-chloro-3-phenyl-indan-l-yl)-3,3-d imethyl-piperazine and D-(-)-tartaric acidin a polar solvent to obtain l-((lR,3S)-6- Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine or a pharmaceutically acceptable salt thereof.
In another embodiment, the present invention relates to, a process for the manufacture of l-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine or a pharmaceutically acceptable salt thereof comprising the steps of
a) mixing trans l-(6-chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine and D- (-)-tartaric acid in a polar solvent;
b) optionally heating the obtained mixture to an appropriate temperature to obtain a solution of the trans l-((6-chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine and D-(-)-tartaric acid;
c) cooling the solution obtained in b) until precipitation;
d) isolating the precipitate obtained in c);
e) optionally drying the precipitate obtained in d); to obtain l-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine or a pharmaceutically acceptable salt thereof.
In a further embodiment, said process comprises a subsequent step in which the precipitate is recrystallised after step d) or e).
In a preferred embodiment, the trans l-((6-chloro-3-phenyl-indan-l-yl)-3,3- dimethyl-piperazine used in the process for manufacture of l-((lR,3S)-6-Chloro-3- phenyl-indan-l-yl)-3,3-dimethyl-piperazine is the trans racemic l-((6-chloro-3-phe nyl-indan-l-yl)-3,3-dimethyl-piperazine.
. In one embodiment l-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl- piperazine hemi D-(-)-tartrate is an intermediate or end product of the process. In a preferred embodiment, said l-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl- piperazine hemi D-(-)-tartrate is in a crystalline form.
In one embodiment, the polar solvent applied in the processes of the present invention are chosen from water, a ketone, an alcohol, an organic acid or mixtures hereof such as water, acetone, ethanol, n-propanol, formic acid or mixtures hereof.
If a salt different from the chiral acid addition salt of the invention is desired, the purified chiral acid addition salt of Compound (I) or (II) may be used as starting material in further processes in which the chiral acid addition salt of the present invention is dissolved, the free base form is optionally obtained, and the desired salt, preferably a pharmaceutically acceptable salt is achieved by precipitation with an appropriate acid.
In one embodiment of the invention, the pharmaceutically acceptable salt is a succinate salt or a malonate salt. In one embodiment, the pharmaceutically acceptable salt is in the form of a crystalline hydrogen succinate salt of Compound (I) e.g., crystal form alpha or beta of the hydrogen succinate salt of Compound (I), or a crystalline hydrogen malonate salt of Compound (I). The succinate salt and malonate salt of Compound (I) are described in WO 2005/016900.
In another embodiment of the invention, the pharmaceutically acceptable salt is a tartrate salt or a malate salt. In one embodiment, the pharmaceutically acceptable salt is in the form of a crystalline hydrogen tartrate salt of Compound (II) or a hydrogen malate salt of Compound (II). The tartrate salt and malate salt of Compound
(II) are described in WO 2006/086985. All references cited herein are hereby incorporated by reference in their entirety and to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein (to the maximum extent permitted by law), regardless of any separately provided incorporation of particular documents made elsewhere herein.
The use of the terms "a" and "an" and "the" and similar referents in the context of describing the invention are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. For example, the phrase "the compound" is to be understood as referring to various compounds of the invention or particular described aspect, unless otherwise indicated.
Unless otherwise indicated, all exact values provided herein are representative of corresponding approximate values (e.g., all exact exemplary values provided with respect to a particular factor or measurement can be considered to also provide a corresponding approximate measurement, modified by "about," where appropriate).
The description herein of any aspect or aspect of the invention using terms such as "comprising", "having," "including," or "containing" with reference to an element or elements is intended to provide support for a similar aspect or aspect of the invention that "consists of, "consists essentially of, or "substantially comprises" that particular element or elements, unless otherwise stated or clearly contradicted by context (e.g., a composition described herein as comprising a particular element should be understood as also describing a composition consisting of that element, unless otherwise stated or clearly contradicted by context).
The invention will be illustrated in the following non-limiting examples. All the examples described for manufacture of Compound (I) implies the use of L-(+)- tartaric acid as the chiral salt-forming acid. All the examples described for
manufacture of Compound (II) implies the use of L(+)-tartaric acid and D(-)-tartaric acid. Examples
HPLC methods:
The chiral purity of 4-((lR,3 S)-6-Chloro-3-phenyl-indan-l-yl)- 1,2,2- trimethyl-piperazine was measured by chiral HPLC chromatography on a Chirapak ADH colomn 250 x 4.6 mm with an eluent: hexane/IPA/N-Ethylethanamine 90:10:0.2, column temperature: 35°C, flow: 0.4 mL /min and UV detection at 230 nm The retention times for the two enantiomers were 8.4 min for the (lS,3R)enantiomer and 9.3 min for Compound (I).
The chiral purity of l-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl- piperazine was established by chiral HPLC chromatography on a Chirapak OD column 250 x 4.6mm with an eluent: heptane/EtOH/DEA 98.4:1.5:0.1, column temperature: 35 0C, flow: 1.0 mL/min and UV detection at 230 nm.
The retention times for the two enantiomers 8.5 min for Compound (II) and 9.5 min for the (lS,3R)enantiomer.
Example 1. 4-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-l,2,2-trimethyl-piperazine L-
(+)-tartrate, acetone.
Trans racemic 4-((6-Chloro-3-phenyl-indan- 1 -yl)- 1 ,2,2-trimethyl-piperazine (3.0 g), was dissolved in acetone (100 mL). L-(+)-tartaric acid (1.3 g) was added and the suspension was heated to 500C until all tartaric acid had dissolved. The warm solution was left for cooling. Precipitation started after 15 minutes. The suspension was stirred overnight at room temperature and the product filtered off and dried in the hood at room temperature. Yield 2.00 g (91 %).
The content of the two enantiomers were (lS,3R)enantiomer=4.6 % and
Compound (I)=95.4 % corresponding to an ee=90.8 % of 4-((lR,3S)-6-Chloro-3-phe nyl-indan- 1 -yl)- 1 ,2,2-trimethyl-piperazine L-(+)-tartrate.
The product (1.50 g) was recrystallised from ethanol (30 mL) at reflux. The solution was stirred overnight while cooled down to room temperature. The product was filtered off and dried in the hood at room temperature.Yield: 1.37 g (87 %). The content of the two enantiomers were (lS,3R)enantiomer=0.8 % and
compound(I)=99.2 % corresponding to an ee=98.4 % of 4-((lR,3S)-6-Chloro-3-phe nyl-indan- 1 -yl)- 1 ,2,2-trimethyl-piperazine L-(+)-tartrate Example 2. 4-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-l,2,2-trimethyl-piperazine L- (+)-tartrate, ethanol.
Trans racemic 4-((6-Chloro-3-phenyl-indan- 1 -yl)- 1 ,2,2-trimethyl-piperazine (1.5 g) was resolved with L-(+)-tartaric acid (0.63 g) from ethanol (50 mL). Yield 0.92 g (87 %), (lS,3R)enantiomer= 0.8 % and Compound (I)=99.2 % corresponding to an ee=98.4 % of 4-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-l,2,2-trimethyl- piperazine L-(+)-tartrate
Example 3. 4-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-l,2,2-trimethyl-piperazine L- (+)-tartrate, propanol.
Trans racemic 4-((6-Chloro-3-phenyl-indan-l-yl)-l,2,2-trimethyl-piperazine (0.75 g) was resolved with L-(+)-tartaric acid (0.32 g) from propanol (25 mL). Yield 0.49 g (89.1 %), (lS,3R)enantiomer=2.2 % and Compound (I)=97.8 % corresponding to an ee=95.6 % of 4-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-l,2,2-trimethyl-piperazine L- (+)-tartrate
Example 4. 4-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-l,2,2-trimethyl-piperazine L- (+)-tartrate, ethanol and formic acid.
Trans racemic 4-((6-Chloro-3-phenyl-indan- 1 -yl)- 1 ,2,2-trimethyl-piperazine (1.5 g) was resolved with L-(+)-tartaric acid (0.38 g) and formic acid (0.097 g) from ethanol (50 mL). Yield 0.56 g (51 %), (lS,3R)enantiomer= 4.8 % and Compound (I)=95.2 % corresponding to an ee=90.4 % of 4-((lR,3S)-6-Chloro-3-phenyl-indan-l- yl)- 1 ,2,2-trimethyl-piperazine L-(+)-tartrate Example 5. 4-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-l,2,2-trimethyl-piperazine L-
(+)-tartrate, ethanol.
Trans racemic 4-((6-Chloro-3-phenyl-indan- 1 -yl)- 1 ,2,2-trimethyl-piperazine
(1.5 g) was resolved with L-(+)-tartaric acid (0.95 g) from ethanol (50 mL). Yield
0.82 g (77 %), (lS,3R)enantiomer= 3.2 % and Compound (I)=96.8 % corresponding to an ee=93.6 % of 4-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-l,2,2-trimethyl- piperazine L-(+)-tartrate
Example 6. l-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine hemi L-(+)-tartrate, acetone.
Trans racemic l-(6-Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine) (2.9 g) was dissolved in acetone (200 mL). L-(+)-tartaric acid (1.3 g) was added and the suspension heated to reflux until almost all had dissolved. A slight turbidity resided, which was filtered off in a folded paper filter. The warm solution was left for cooling to room temperature and precipitation started very slowly after an hour. The suspension was stirred overnight at room temperature, and the product was filtered off, very slowly, and dried in the hood at room temperature. Yield 2.74 g (65 %). The content of the two enantiomers were Compound (II)= 58.6 % and
(lS,3R)enantiomer=41.4 % corresponding to an ee=17.2 % of l-((lR,3S)-6-chloro-3- phenyl-indan-l-yl)-3,3-dimethyl-piperazine hemi L-(+)-tartrate.
The product (2.00 g) was recrystallised from a mixture of ethanol (100 mL) and water (10 mL) at reflux. The solution was stirred while cooled down to room temperature and stirred for a week at room temperature. The precipitate was filtered off and dried in the hood at room temperature. Yield 0.81 g (40.5 %). The content of the two enantiomers were Compound (II)=3.9 % and (lS,3R)enantiomer=96.1 % corresponding to an ee=92.2 % of l-((lS,3R)-6-Chloro-3-phenyl-indan-l-yl)-3,3- dimethyl-piperazine hemi L-(+)-tartrate i.e. the recrystallisation from aqueous ethanol have reversed the most abundant of the enantiomers giving a yield of 53 % when the content of the chiral antipodes in the starting material are taken into account.
Example 7. l-((lS,3R)-6-Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine hemi L-(+)-tartrate, ethanol.
Trans racemic l-(6-Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine (2.9 g) was resolved with L-(+)-tartaric acid (1.3 g) from ethanol (350 mL). Yield 1.49 g (42 %), Compound (II)=2.8 % and (lS,3R)enantiomer=97.2 % corresponding to an ee=94.4 % of l-((lS,3R)-6-Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine hemi L-(+)-tartrate.
Example 8. l-((lS,3R)-6-Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine hemi L-(+)-tartrate, acetone.
Trans racemic l-(6-Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine
(0.85 g) was resolved with L-(+)-tartaric acid (0.37 g) from acetone (25 mL) and water (2.5 mL). Yield 0.61 g (51 %), Compound (II)=49.8 % and
(lS,3R)enantiomer=50.2 % corresponding to an ee=0.4 % i.e. the racemate.
Example 9. l-((lS,3R)-6-Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine hemi
L-(+)-tartrate, ethanol.
Trans racemic l-(6-Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine
(1.45 g) was resolved with L-(+)-tartaric acid (0.65 g) from ethanol (50 mL). Yield 0.62 g (56 %), Compound (II)=2.2 % and (lS,3R)enantiomer=97.8 % corresponding to an ee=95.6 % of l-((lS,3R)-6-Chloro-3-phenyl-indan4-yl)-3,3-dimethyl- piperazine hemi L-(+)-tartrate. Example 10. l-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine hemi D-(-)-tartrate, ethanol and formic acid.
Trans racemic l-(6-Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine (1.5 g) was resolved with D-(-)-tartaric acid (0.40 g) and formic acid (0.10 mL) from ethanol (50 mL). Yield 0.78 g (71 %), Compound (II)=99.0 % and
(lS,3R)enantiomer=1.0 % corresponding to an ee=98.0 % of l-((lR,3S)-6-Chloro-3- phenyl-indan-l-yl)-3,3-dimethyl-piperazine hemi D-(-)-tartrate.
Example 11. l-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine D-(- Vtartrate, ethanol.
Trans racemic l-(6-Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine
(0.94 g) was resolved with D-(-)-tartaric acid (0.94 g) from ethanol (150 mL). Yield 0.61 g (59 %), compound(II)=98.3 % and (Sl,R3)enantiomer=1.7 % corresponding to an ee=96.6 % of l-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine hemi D-(-)-tartrate.

Claims

Claims
1. A process for the manufacture of 4-((lR,3 S)-6-Chloro-3 -phenyl- indan- 1-yl)- 1,2,2-trimethyl-piperazine or a pharmaceutically acceptable salt thereof comprising the step of mixing trans 4-(6-chloro-3-phenyl-indan-l-yl)-l,2,2-trimethyl-piperazine with L-(+)-tartaric acid in a polar solvent to obtain 4-((lR,3S)-6-Chloro-3-phenyl- indan-l-yl)-l,2,2-trimethyl-piperazine or a pharmaceutically acceptable salt thereof.
2. The process according to claim 1, wherein the mixture of trans 4-(6-chloro-3- phenyl- indan- 1 -yl)- 1 ,2,2-trimethyl-piperazine and L-(+)-tartaric acid in a polar solvent is brought into conditions suitable for obtaining a solution of the trans 4-(6- chloro-3-phenyl- indan- l-yl)-l,2,2-trimethyl-piperazine and L-(+)-tartaric acid.
3. The process according to any of claims 1-2 wherein the mixture of trans 4-(6- chloro-3-phenyl- indan- l-yl)-l,2,2-trimethyl-piperazine and L-(+)-tartaric acid in a polar solvent is heated to an appropriate temperature to obtain a solution of the trans 4-(6-chloro-3 -phenyl- indan- l-yl)-l,2,2-trimethyl-piperazine and L-(+)-tartaric acid.
4. A process for the manufacture of 4-((lR,3 S)-6-Chloro-3 -phenyl- indan- 1-yl)- 1,2,2-trimethyl-piperazine or a pharmaceutically acceptable salt thereof comprising the step of precipitating a product from a solution comprising trans 4-(6-chloro-3-phe nyl- indan- 1-yl)- 1,2,2-trimethyl-piperazine and L-(+)-tartaric acid in a polar solvent to obtain 4-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-l,2,2-trimethyl-piperazine or a pharmaceutically acceptable salt thereof.
5. A process for the manufacture of 4-((lR,3 S)-6-Chloro-3 -phenyl- indan- 1-yl)- 1,2,2-trimethyl-piperazine or a pharmaceutically acceptable salt thereof comprising the steps of
a) mixing trans 4-(6-chloro-3-phenyl- indan- 1 -yl)- 1 ,2,2-trimethyl-piperazine and L-(+)-tartaric acid in a polar solvent;
b) optionally heating the obtained mixture to an appropriate temperature to obtain a solution of the trans 4-(6-chloro-3-phenyl- indan- 1-yl)- 1,2,2-trimethyl-piperazine and L-(+)-tartaric acid;
c) cooling the solution obtained in b) until precipitation; d) isolating the precipitate obtained in c);
e) optionally drying the precipitate obtained in d);
to obtain 4-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-l,2,2-trimethyl-piperazine or a pharmaceutically acceptable salt thereof.
6. The process according to claim 5 which process comprises a subsequent step in which the precipitate is recrystallised after step d) or e)
7. The process according to any of claims 1-6, wherein said trans 4-(6-chloro-3- phenyl- indan- 1 -yl)- 1 ,2,2-trimethyl-piperazine is the trans racemic 4-(6-chloro-3-phe nyl-indan- 1 -yl)- 1 ,2,2-trimethyl-piperazine.
8. The process according to any of claims 1-7, wherein 4-((lR,3S)-6-Chloro-3- phenyl- indan- l-yl)-l,2,2-trimethyl-piperazine L-(+)-tartrate is an intermediate or end product of the process.
9. The process according to claim 8, wherein said 4-((lR,3S)-6-Chloro-3-phenyl- indan-l-yl)-l,2,2-trimethyl-piperazine L-(+)-tartrate is obtained in a crystalline form.
10. The process according to any of claims 1-9 wherein said polar solvent is chosen from water, alcohols, ketones, organic acids or mixtures hereof.
11. The process according to claim 10 wherein said polar solvent is chosen from water, acetone, ethanol, n-propanol, formic acid or mixtures hereof.
12. A compound which is 4-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)- 1,2,2- trimethyl-piperazine L-(+)-tartrate.
13. A compound according to claim 12, wherein said 4-((lR,3S)-6-Chloro-3-phe nyl- indan- l-yl)-l,2,2-trimethyl-piperazine L-(+)-tartrate is in a crystalline form.
14. A process for the manufacture of 1 -((1R,3 S)-6-Chloro-3 -phenyl- indan- 1-yl)- 3,3-dimethyl-piperazine or a pharmaceutically acceptable salt thereof comprising the step of mixing trans l-(6-chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine with D-(-)-tartaric acid in a polar solvent to obtain l-((lR,3S)-6-Chloro-3-phenyl-indan-l- yl)-3,3-dimethyl-piperazine or a pharmaceutically acceptable salt thereof.
15. The process according to claim 14, wherein the mixture of trans l-((6-chloro- 3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine and D-(-)-tartaric acid in a polar solvent is brought into conditions suitable for obtaining a solution of the trans l-((6-chloro-3- phenyl-indan-l-yl)-3,3-dimethyl-piperazine D-(-)-tartaric acid.
16. The process according to any of claims 14-15 wherein the mixture of trans 1- ((6-chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine and D-(-)-tartaric acid in a polar solvent is heated to an appropriate temperature to obtain a solution of the trans l-((6-chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine and D-(-)-tartaric acid.
17. A process for the manufacture of l-((lR,3S)-6-Chloro-3 -phenyl- indan-1-yl)- 3,3-dimethyl-piperazine or a pharmaceutically acceptable salt thereof comprising the step of precipitating a product from a solution comprising trans 4-(6-chloro-3-phenyl- indan-l-yl)-3,3-dimethyl-piperazine and D-(-)-tartaric acid in a polar solvent to obtain 4-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine or a
pharmaceutically acceptable salt thereof.
18. A process for the manufacture of 1 -((1R,3 S)-6-Chloro-3 -phenyl- indan-1-yl)- 3,3-dimethyl-piperazine or a pharmaceutically acceptable salt thereof comprising the steps of
a) mixing trans l-(6-chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine and D- (-)-tartaric acid in a polar solvent;
b) optionally heating the obtained mixture to an appropriate temperature to obtain a solution of the trans l-((6-chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine and D-(-)-tartaric acid;
c) cooling the solution obtained in b) until precipitation;
d) isolating the precipitate obtained in c);
e) optionally drying the precipitate obtained in d);
to obtain l-((lR,3S)-6-Chloro-3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine or a pharmaceutically acceptable salt thereof.
19. The process according to claim 18 which process comprises a subsequent step in which the precipitate is recrystallised after step d) or e).
20. The process according to any of claims 14-19, wherein said trans l-((6-chloro- 3-phenyl-indan-l-yl)-3,3-dimethyl-piperazine is the trans racemic l-((6-chloro-3-phe nyl-indan-l-yl)-3,3-dimethyl-piperazine.
21. The process according to any of claims 14-20, wherein l-((lR,3S)-6-Chloro-3- phenyl-indan-l-yl)-3,3-dimethyl-piperazine hemi D-(-)-tartrate is an intermediate or end product of the process.
22. The process according to claim 21, wherein said l-((lR,3S)-6-Chloro-3-phe nyl-indan-l-yl)-3,3-dimethyl-piperazine hemi D-(-)-tartrate is obtained in a crystalline form
23. The process according to any of claims 14-22, wherein said polar solvent is chosen from water, alcohols, ketones, organic acids or mixtures hereof.
24. The process according to claim 23, wherein said polar solvent is chosen from water, acetone, ethanol, n-propanol, formic acid or mixtures hereof.
PCT/DK2010/050177 2009-07-07 2010-07-07 Manufacture of 4-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and 1-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-3,3-dimethyl-piperazine WO2011003423A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2010268892A AU2010268892B2 (en) 2009-07-07 2010-07-07 Manufacture of 4-((1R,3S)- 6-Chloro-3-phenyl-indan-1-yl) -1,2,2-trimethyl-piperazine and 1-((1R,3S)-6-Chloro-3-phenyl-indan-1-yl) -3,3-dimethyl-piperazine
CN2010800309960A CN102471289A (en) 2009-07-07 2010-07-07 Manufacture of 4-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and 1-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-3,3-dimethyl-piperazine
US13/382,378 US8501947B2 (en) 2009-07-07 2010-07-07 Manufacture of 4-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and 1-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-3,3-dimethyl-piperazine
JP2012518754A JP2012532153A (en) 2009-07-07 2010-07-07 4-((1R, 3S) -6-chloro-3-phenyl-indan-1-yl) -1,2,2-trimethyl-piperazine, and 1-((1R, 3S) -6-chloro-3- Preparation of phenyl-indan-1-yl) -3,3-dimethyl-piperazine
CA2766607A CA2766607A1 (en) 2009-07-07 2010-07-07 Manufacture of 4-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and 1-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-3,3-dimethyl-piperazine
EP10730348A EP2451789A1 (en) 2009-07-07 2010-07-07 Manufacture of 4-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and 1-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-3,3-dimethyl-piperazine

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22355109P 2009-07-07 2009-07-07
DKPA200900835 2009-07-07
DKPA200900835 2009-07-07
US61/223,551 2009-07-07

Publications (1)

Publication Number Publication Date
WO2011003423A1 true WO2011003423A1 (en) 2011-01-13

Family

ID=43428803

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2010/050177 WO2011003423A1 (en) 2009-07-07 2010-07-07 Manufacture of 4-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and 1-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-3,3-dimethyl-piperazine

Country Status (9)

Country Link
US (1) US8501947B2 (en)
EP (1) EP2451789A1 (en)
JP (1) JP2012532153A (en)
CN (1) CN102471289A (en)
AR (1) AR077456A1 (en)
AU (1) AU2010268892B2 (en)
CA (1) CA2766607A1 (en)
TW (1) TW201102370A (en)
WO (1) WO2011003423A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012093165A1 (en) * 2011-01-07 2012-07-12 H. Lundbeck A/S Method for resolution of 4-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and 1-((1r,3s)-6-chloro-3-phenyl-indan, 1-yl)-3,3-dimethyl-piperazine
WO2014096151A2 (en) 2012-12-19 2014-06-26 H. Lundbeck A/S 6-chloro-3-(phenyl-d5)-inden-1-one and use thereof
WO2020114853A1 (en) 2018-12-03 2020-06-11 H. Lundbeck A/S Prodrugs of 4-((1r,3s)-6-chloro-3-phenyl-2,3-dihydro-1h-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1/r,3s)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1h-inden-1-yl)-2,2-dimethy-1-(methyl-d3)piperazine
US12116355B2 (en) 2011-06-20 2024-10-15 H. Lundbeck A/S Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993022293A1 (en) 1992-04-28 1993-11-11 H. Lundbeck A/S 1-piperazino-1,2-dihydroindene derivatives
WO2005016900A1 (en) 2003-08-18 2005-02-24 H. Lundbeck A/S Succinate and malonate salt of trans-4-(ir,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament
WO2006086985A1 (en) 2005-02-16 2006-08-24 H. Lundbeck A/S Tartrate and malate salts of trans-1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
WO2006086984A1 (en) 2005-02-16 2006-08-24 H. Lundbeck A/S Process for making trans-1-((1r, 3s)-6-chloro-3-phenylindan-1-yl)-3, 3-dimethylpiperazine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200640891A (en) * 2005-02-16 2006-12-01 Lundbeck & Co As H Tartrate and malate salts of a pharmarceutical compound

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993022293A1 (en) 1992-04-28 1993-11-11 H. Lundbeck A/S 1-piperazino-1,2-dihydroindene derivatives
WO2005016900A1 (en) 2003-08-18 2005-02-24 H. Lundbeck A/S Succinate and malonate salt of trans-4-(ir,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament
WO2005016901A1 (en) 2003-08-18 2005-02-24 H. Lundbeck A/S Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
WO2006086985A1 (en) 2005-02-16 2006-08-24 H. Lundbeck A/S Tartrate and malate salts of trans-1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
WO2006086984A1 (en) 2005-02-16 2006-08-24 H. Lundbeck A/S Process for making trans-1-((1r, 3s)-6-chloro-3-phenylindan-1-yl)-3, 3-dimethylpiperazine
US20080153847A1 (en) * 2005-02-16 2008-06-26 H. Lundbeck A/S Process for Making Trans-1-((1R,3S)-6-Chloro-3-Phenylindan-1-Yl)-3,3-Dimethylpiperazine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BOGESO ET AL., J. MED. CHEM., vol. 38, 1995, pages 4380 - 4392
BOGESO K P ET AL: "ENHANCED D1 AFFINITY IN A SERIES OF PIPERAZINE RING SUBSTITUTED 1-PIPERAZINO-3-ARYLINDANS WITH POTENTIAL ATYPICAL ANTIPSYCHOTIC ACTIVITY", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US LNKD- DOI:10.1021/JM00022A004, vol. 38, no. 22, 1 January 1995 (1995-01-01), pages 4380 - 4392, XP008037648, ISSN: 0022-2623 *
KLAUS P. BOGESO, DRUG HUNTING, THE MEDICINAL CHEMISTRY OF 1-PIPERAZINO-3-PHENYLINDANS AND RELATED COMPOUNDS, 1998, pages 47

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012093165A1 (en) * 2011-01-07 2012-07-12 H. Lundbeck A/S Method for resolution of 4-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and 1-((1r,3s)-6-chloro-3-phenyl-indan, 1-yl)-3,3-dimethyl-piperazine
US12116355B2 (en) 2011-06-20 2024-10-15 H. Lundbeck A/S Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia
WO2014096151A2 (en) 2012-12-19 2014-06-26 H. Lundbeck A/S 6-chloro-3-(phenyl-d5)-inden-1-one and use thereof
WO2020114853A1 (en) 2018-12-03 2020-06-11 H. Lundbeck A/S Prodrugs of 4-((1r,3s)-6-chloro-3-phenyl-2,3-dihydro-1h-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1/r,3s)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1h-inden-1-yl)-2,2-dimethy-1-(methyl-d3)piperazine
US11535600B2 (en) 2018-12-03 2022-12-27 H. Lundbeck A/S Prodrugs of 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazine
US12071416B2 (en) 2018-12-03 2024-08-27 H. Lundbeck A/S Prodrugs of 4-( (1R, 3S)-6-chloro-3-phenyl-2, 3-dihydro-1H-inden-1-yl)-1,2, 2-trimethylpiperazine and 4-( (1R, 3S)-6-chloro-3-(phenyl-D5)-2, 3-dihydro-1H-inden-1-yl)-2, 2-dimethyl-1 (methyl-D3) piperazine

Also Published As

Publication number Publication date
EP2451789A1 (en) 2012-05-16
AR077456A1 (en) 2011-08-31
US8501947B2 (en) 2013-08-06
US20120142923A1 (en) 2012-06-07
JP2012532153A (en) 2012-12-13
AU2010268892A1 (en) 2012-02-02
AU2010268892B2 (en) 2015-03-26
TW201102370A (en) 2011-01-16
CN102471289A (en) 2012-05-23
CA2766607A1 (en) 2011-01-13

Similar Documents

Publication Publication Date Title
EP2398785A1 (en) Purification of 1-ý2-(2,4-dimethylphenylsulfanyl)phenyl¨piperazine
EP2268617B1 (en) Process for the resolution of isoquinoline derivatives
WO2008062460A2 (en) Crystalline forms of pregabalin
CA3085208A1 (en) Enantiomeric separation of racemic nicotine by addition of an o,o'-disubstituted tartaric acid enantiomer
JP2007314537A (en) Method for producing benzopyran-2-ol derivative
EP1773793A2 (en) Process for the preparation of pramipexole by chiral chromatography
US8501947B2 (en) Manufacture of 4-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and 1-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-3,3-dimethyl-piperazine
US20120004463A1 (en) Resolution of 4,5-dimethoxy-1-(methylaminomenthyl)-benzocyclobutane
MX2007009816A (en) Tartrate and malate salts of trans-1-((1r,3s)-6-chloro-3- phenylindan-1-yl)-3,3-dimethylpiperazine.
JP5595404B2 (en) Process for the preparation of optically active (S)-(-)-2- (N-propylamino) -5-methoxytetralin and (S)-(-)-2- (N-propylamino) -5-hydroxytetralin compounds
JP2011516519A (en) Polymorph of argatroban monohydrate and its synthesis
WO2016038422A1 (en) Process for the preparation of optically enriched adrenaline
EP2661427A1 (en) Method for resolution of 4-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and 1-((1r,3s)-6-chloro-3-phenyl-indan, 1-yl)-3,3-dimethyl-piperazine
WO2010046360A1 (en) Process for the preparation of substantially optically pure repaglinide and precursors thereof
JP2010520251A (en) Synthesis of GLYT-1 inhibitor
EP2542530A2 (en) Process for the preparation of 2-(cyclohexylmethyl)-n-{2- [(2s)-1-methylpyrrolidin-2-yl]ethyl}-1, 2, 3, 4- tetrahydroisoquinoline-7-sulfonamide
WO2005105784A1 (en) Diastereoselective synthesis process for the preparation of imidazole compounds
JP2012521392A (en) Method for the separation of enantiomers of dihydro-1,3,5 triazine racemate using a preferential crystallization method
JP2011521007A (en) Process for the production of enantiomerically pure (S) -1-phenyl-1,2,3,4-tetrahydroisoquinoline
EP1899293A2 (en) Process for preparing 3,3-diarylpropylamines
Periasamy et al. Simple and convenient methods for synthesis, resolution and application of aminonaphthols
JP4205130B2 (en) Toremifene crystallization method
CA2543575A1 (en) New process for preparing an optically pure 2-morphinol derivative
EP2177221A1 (en) Process for the preparation of substantially optically pure Repaglinide and precursors thereof
WO2008038122A2 (en) Processes for the preparation of 7-substituted 3,3-dimethyl-4-amino-piperidino-quinolone carboxylic acid derivatives

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080030996.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10730348

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2766607

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 159/CHENP/2012

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2012518754

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2010268892

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2010730348

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2010268892

Country of ref document: AU

Date of ref document: 20100707

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13382378

Country of ref document: US